INREBIC Trademark

Trademark Overview


On Friday, April 24, 2020, a trademark application was filed for INREBIC with the United States Patent and Trademark Office. The USPTO has given the INREBIC trademark a serial number of 88886323. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 13, 2022. This trademark is owned by Impact Biomedicines, Inc.. The INREBIC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy
inrebic

General Information


Serial Number88886323
Word MarkINREBIC
Filing DateFriday, April 24, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 13, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, September 14, 2021

Trademark Statements


Description of MarkThe mark consists of the stylized wording "INREBIC" with a design of three triangles cascading appearing above the wording.
Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 5, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImpact Biomedicines, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameImpact Biomedicines, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, June 13, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 13, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, November 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021PUBLISHED FOR OPPOSITION
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 5, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 19, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 19, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 19, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, January 21, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, January 21, 2021FINAL REFUSAL E-MAILED
Thursday, January 21, 2021FINAL REFUSAL WRITTEN
Wednesday, January 20, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 19, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 19, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, July 18, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, July 18, 2020NON-FINAL ACTION E-MAILED
Saturday, July 18, 2020NON-FINAL ACTION WRITTEN
Saturday, July 18, 2020ASSIGNED TO EXAMINER
Wednesday, May 6, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, May 5, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, April 28, 2020NEW APPLICATION ENTERED IN TRAM